Market Place
Sourcing Support
JanOne Regains Compliance with Nasdaq`s Listing Requirements
15 Mar 2024 //
PR NEWSWIRE
JanOne to Present at the Dawson James 8th Annual Investment Conference
21 Sep 2023 //
PR NEWSWIRE
JanOne to Present In Person & by Video H.C. Wainwright`s 25th AnnualConference
31 Aug 2023 //
PR NEWSWIRE
JanOne Wins "Best Abstract" Award at the Annual Meeting
25 Aug 2023 //
PR NEWSWIRE
JanOne Announces Registered Direct Offering Priced under Nasdaq Rules
18 Aug 2023 //
PR NEWSWIRE
JanOne files international patent appl. for methods of using low dose naltrexone
28 Jun 2023 //
PR NEWSWIRE
JanOne Completes Pre-IND Meeting with FDA on Jan123
18 Apr 2023 //
PR NEWSWIRE
JanOne to Present Data On Non-Opioid Candidates to Treat Pain on April 15, 2023
13 Apr 2023 //
PR NEWSWIRE
JanOne Announces Closing of Direct Offering of Stock Priced At-The-Market
24 Mar 2023 //
PR NEWSWIRE
JanOne Announces Registered Direct Offering of Common Stock Priced At-The-Market
23 Mar 2023 //
PR NEWSWIRE
JanOne Welcomes John Bonfiglio -- Veteran Biotech Executive
23 Mar 2023 //
PR NEWSWIRE
JanOne to Present Important Trial Results at Annual Meeting
22 Feb 2023 //
PR NEWSWIRE
JanOne Charts Ambitious Strategic Course for Non-Addictive Pain Management
26 Jan 2023 //
PR NEWSWIRE
JanOne Inc. Completes Acquisition of Soin Therapeutics, LLC
10 Jan 2023 //
PR NEWSWIRE
JanOne Inc. Executes Term Sheet to Acquire Soin Therapeutics LLC
16 Sep 2022 //
BIOSPACE
JanOne Inc. Announces an Improved Formulation of JAN101
28 Jun 2022 //
PRNEWSWIRE
JanOne Nabs U.S. Patent Covering Method of Improving Nerve Function with JAN101
07 Jun 2022 //
PRNEWSWIRE
JanOne Sells GeoTraq to SPYR Technologies in a $13.5 Million Transaction
31 May 2022 //
PRNEWSWIRE
JanOne Inc. Develops Plan for Treating Methamphetamine Use Disorder
04 Jan 2022 //
PRNEWSWIRE
JanOne Acquires an Option for Treating Methamphetamine Use Disorder
07 Dec 2021 //
PRNEWSWIRE
JanOne as Trial Manager for Phase 2b Study of JAN101 Peripheral Artery Disease
22 Jul 2021 //
PRNEWSWIRE
JanOne as Trial Manager for Phase 2b Study of JAN101 Peripheral Artery Disease
22 Jul 2021 //
PRNEWSWIRE
JanOne Readies Clinical Supply of Lead Product Candidate JAN101
23 Jun 2021 //
PRNEWSWIRE
JanOne Engages DC Consulting LLC for Government and Private Sector Initiatives
10 Jun 2021 //
PRNEWSWIRE
JanOne Advances Toward Initiation of Phase 2b Trial for JAN101
08 Jun 2021 //
PRNEWSWIRE
JanOne Announces Closing of $6.0 Million Common Stock Offering
02 Feb 2021 //
PRNEWSWIRE
JanOne Prices $6.0 Million Common Stock Offering
29 Jan 2021 //
PRNEWSWIRE
JanOne Successfully Begins Production of JAN101 cGMP Batch
24 Sep 2020 //
PRNEWSWIRE
JanOne Issues September 2020 Shareholder Letter
22 Sep 2020 //
PRNEWSWIRE
JanOne Announces Strategic Plan to Divest its Legacy Businesses
16 Sep 2020 //
PRNEWSWIRE
JanOne Prepares for GMP Production
08 Sep 2020 //
CONTRACT PHARMA
JanOne confirms stability data of JAN101 development batch
03 Sep 2020 //
PRNEWSWIRE
JanOne Selects Partner for Bottling and Labeling of JAN101
28 Aug 2020 //
PRNEWSWIRE
JanOne Advances its Potential Peripheral Artery Disease Covid-19 Inflammation
26 Aug 2020 //
PRNEWSWIRE
JanOne Advances its Potential Peripheral Artery Disease & Covid-19 Inflammation
26 Aug 2020 //
PRNEWSWIRE
JanOne Readies for Clinical GMP Manufacturing Run
20 Aug 2020 //
CONTRACTPHARMA
JanOne Engages CATO SMS, a World-Leading CRO, to Assist in the Devp of JAN101
06 Aug 2020 //
PRNEWSWIRE
JanOne Changes Internal Drug Candidate Name from TV1001SR to JAN101
04 Aug 2020 //
PRNEWSWIRE
